Business ❯ Corporate Strategy ❯ Mergers and Acquisitions ❯ Market Competition

Drug Pricing

Merck and Other Drugmakers Weigh Bids for Inhibrx’s Keytruda-Linked Cancer Drug

The interest highlights demand for add-on therapies that could bolster Keytruda before key patents expire in 2028.